Versatope Biotechnology Platform
Our clinical stage company uses designer extracellular nano-vesicles to provide cross-strain immunity to infectious diseases, including Influenza, malaria and targeted therapeutics for cancer.
We have a versatile platform based on molecular engineering of proprietary cell lines that produce Recombinant Extracellular Transport Vesicles (RET-V's).
The Power of Versatope's Vesicles
- Display Multiple Viral Variants on a Single Vesicle
- Design More Effective Vaccines
- Deliver therapeutic RNA directly into cancer cells
- Protect Against Emerging Strains
- Confer Long-Term Immunity
- Rapid Synthesis, Scale up and Distribution
- Thermostable
A 3-D View of Versatope's Vaccine Design
Take a voyage inside Versatope's vaccine vesicles and learn how we design multi-strain vaccines using probiotic vesicles and why this gives us a competitive advantage over single strain vaccines.
Hear our team describe Versatope's state of the art manufacturing and analytical equipment that enables us to deliver immunity.